U.S. markets close in 4 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0460-0.0047 (-9.27%)
As of 03:07PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0507
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0432 - 0.0484
52 Week Range0.0401 - 0.3490
Avg. Volume168,849
Market Cap19.078M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.0860
Earnings DateApr 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Aurora Cannabis Inc.Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that include Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • PR Newswire

    Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) has classified PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). The designation represents PPP004's third orphan drug designation (ODD) as a treatment for EB.

  • PR Newswire

    Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of the first tranche of the previously announced private placement with Cannvalate Pty Ltd ("Cannvalate"), resulting in the issuance of 8,236,681 common shares in the capital of the Company (the "Common Shares"), representing 1.95% of the issued and outstanding Common Shares, at a price of $0.06 per Common Share

  • CNW Group

    Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.